SG Analytics (SGA) helps you evaluate evidence of the value of a new drug or product for reimbursement and healthcare payers using AI/ML tools for crisp and precise solutions.
Health economics and outcomes research (HEOR) is conducted to analyze DAILY and positive health outcomes by studying healthcare providers, hospitals, clinics, managed care, and public health promotion activities in different set-ups.
SGA started its health economics and outcomes research (HEOR) services and solutions in 2020. It is one of the most sought-after services from our pharmaceutical clients. Our health economics and outcomes research consultants use ML tools to scrape precise real-world data pertinent to medical research and disease areas and transform a cumbersome process into a much easier, white-labeled customized... Read More
The relevance of HEOR is increasing with each passing day, as it provides valuable information to the decision-makers in drug, diagnostics, and medical product companies, as well as healthcare providers and patients for optimal allocation of healthcare resources. Health economics outcomes research is a function within a pharma or life sciences company that supports strategy and marketing teams to generate evidence of the value of a new drug or diagnostic kit or product or other intervention, which will need reimbursement in the future. Millions of dollars are spent on getting cumbersome HEOR reports from the market.
Why SGA
Industry Leaders
SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.
12+ Languages
Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.
Whitepapers
Emergence of Novel Immune - Mediated Therapies
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
Whitepapers
Future Trends and Technological Advances in Vaccine Treatment and Disease Prevention
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
Whitepapers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
CASE STUDIES
We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
